Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
RGC stock price ended at $26.95 on 月曜日, after dropping 1.96%
On the latest trading day Apr 27, 2026, the stock price of RGC fell by 1.96%, dropping from $27.50 to $26.95. During the session, the stock saw a volatility of 2.31%, with prices oscillating between a daily low of $26.88 and a high of $27.50. On the latest trading day, the trading volume for RGC decreased by 47.7K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 14.4K shares were traded, with a market value of approximately $13.3B.